Received Apr 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
consumer received 3 doses of GARDASIL-9 at 8 years old, 8 years and 6 months old, and 9 year and 7 months old.; No additional AE reported; d 3 doses of GARDASIL-9 at 8 years old, 8 years and 6 months old, and 9 year and 7 months old; d 3 doses of GARDASIL-9 at 8 years old, 8 years and 6 months old, and 9 year and 7 months old; This spontaneous report was received from a pharmacist and refers to a child of unknown gender. The patient's concurrent conditions, medical history and concomitant therapies were not provided. On an unknown date, reported as at 8 years old, the patient was vaccinate with the first dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) (dose, route of administration, lot # and expiration date were not provided) for prophylaxis (Product administered to patient of inappropriate age). On an unknown date in 2023, reported as at 8 years and 6 months old the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) (dose, route of administration, lot # and expiration date were not provided) for prophylaxis (Inappropriate schedule of product administration). On an unknown date in 2024, reported as at 9 years and 7 months old, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) (dose, route of administration, lot # and expiration date were not provided) for prophylaxis (Inappropriate schedule of product administration). No adverse events were reported.